NCT02343718View on ClinicalTrials.gov

Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 24, 2015

Primary Completion Date

September 28, 2017

Study Completion Date

January 16, 2019

Conditions
Recurrent LymphomaRefractory LymphomaSolid TumoursCentral Nervous System
Interventions
DRUG

Vinblastine

DRUG

Temsirolimus

Trial Locations (6)

V6H 3V4

Children's and Women's Health Centre of BC Branch, Vancouver

B3K 6R8

Izaak Walton Killam (IWK) Health Centre, Halifax

L8N 3Z5

McMaster Children's Hospital, Hamilton

K1H 8L1

Children's Hospital of Eastern Ontario, Ottawa

M5G 1X8

Hospital for Sick Children, Toronto

H3T 1C5

CHU Sainte-Justine, Montreal

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK

NCT02343718 - Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours | Biotech Hunter | Biotech Hunter